Juno Therapeutics, Inc. (NASDAQ:JUNO) Upgraded at Vetr Inc.

Vetr upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a sell rating to a hold rating in a research report report published on Monday, July 31st. They currently have $28.85 target price on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on the company. Wedbush reiterated a neutral rating and issued a $24.00 target price on shares of Juno Therapeutics in a research note on Friday, May 5th. BidaskClub raised Juno Therapeutics from a buy rating to a strong-buy rating in a report on Tuesday, June 27th. Morgan Stanley reduced their price target on Juno Therapeutics from $27.00 to $26.00 and set an equal weight rating for the company in a report on Monday, May 8th. Citigroup Inc. reduced their price target on Juno Therapeutics from $34.00 to $30.00 and set a buy rating for the company in a report on Tuesday, April 4th. Finally, FBR & Co reissued a hold rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. Juno Therapeutics presently has an average rating of Hold and an average price target of $30.63.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at 26.99 on Monday. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $34.35. The company’s 50 day moving average price is $28.75 and its 200-day moving average price is $24.87. The firm’s market cap is $2.83 billion.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter last year, the business posted ($0.64) earnings per share. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. On average, equities research analysts anticipate that Juno Therapeutics will post ($3.13) EPS for the current year.

In related news, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total transaction of $262,500.00. Following the completion of the transaction, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at $22,085,670. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley acquired 20,000 shares of Juno Therapeutics stock in a transaction that occurred on Friday, May 26th. The shares were purchased at an average cost of $24.76 per share, with a total value of $495,200.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 8,053,500 shares of company stock valued at $217,594,440. 15.26% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its position in Juno Therapeutics by 1.2% in the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock valued at $248,481,000 after buying an additional 135,908 shares during the last quarter. Vanguard Group Inc. increased its position in Juno Therapeutics by 2.1% in the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after buying an additional 131,864 shares during the last quarter. BlackRock Inc. increased its position in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock valued at $128,357,000 after buying an additional 110,503 shares during the last quarter. State Street Corp increased its position in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after buying an additional 222,754 shares during the last quarter. Finally, Capital World Investors increased its position in Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock valued at $72,483,000 after buying an additional 295,000 shares during the last quarter. 65.03% of the stock is owned by institutional investors.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

To view Vetr’s full report, visit Vetr’s official website.